RANIRani Therapeutics Holdings,...

Nasdaq ranitherapeutics.com


$ 7.01 $ -0.14 (-1.96 %)    

Thursday, 09-May-2024 09:42:19 EDT
QQQ $ 439.91 $ -0.55 (-0.12 %)
DIA $ 391.82 $ 1.71 (0.44 %)
SPY $ 518.17 $ 0.76 (0.15 %)
TLT $ 89.90 $ -0.31 (-0.34 %)
GLD $ 215.80 $ 1.04 (0.48 %)
$ 7.15
$ 7.01
$ 0.00 x 0
$ 0.00 x 0
$ 7.01 - $ 7.01
$ 1.82 - $ 8.75
99,095
na
186.14M
$ 0.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-06-2024 03-31-2024 10-Q
2 03-20-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-16-2021 09-30-2021 10-Q
12 09-13-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rani-therapeutics-to-present-data-on-oral-delivery-of-an-ustekinumab-biosimilar-via-the-ranipill-capsule-at-digestive-disease-week-2024

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutic...

 hc-wainwright--co-maintains-buy-on-rani-therapeutics-hldgs-raises-price-target-to-13

HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and raises the pr...

 rani-therapeutics-hldgs-q1-eps-029-beats-031-estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate ...

 equifax-reports-weak-sales-joins-synovus-financial-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday.

 why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

 netflix-to-rally-over-15-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 canaccord-genuity-maintains-buy-on-rani-therapeutics-hldgs-lowers-price-target-to-9

Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target...

 hc-wainwright--co-maintains-buy-on-rani-therapeutics-hldgs-lowers-price-target-to-12

HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the pr...

 rani-therapeutics-hldgs-q4-2023-gaap-eps-027-beats-031-estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate ...

 earnings-scheduled-for-march-20-2024

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per s...

 wedbush-reiterates-outperform-on-rani-therapeutics-hldgs-maintains-8-price-target

Wedbush analyst Andreas Argyrides reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform and maintains $8 price ...

 rani-therapeutics-announces-topline-results-from-phase-1-study-of-oral-anti-interleukin-1223-antibody

- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events -- Celltrion has...

 rani-therapeutics-announces-preclinical-pharmacodynamic-data-on-transenteric-delivery-of-glp-1-incretin-triagonist

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –- P...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION